Intelivation’s Hammerdesis Interphalangeal Fusion System Gains FDA Nod

Intelivation Technologies has received U.S. Food and Drug Administration (FDA) clearance for its Hammerdesis interphalangeal fusion system.
 
Hammerdesis allows correction of hammertoe deformities and degenerative issues by affixing a “distinctively designed” implant to the toe joint. The operation, according to Intelivation, saves intraoperative time and yields cost savings in the ambulatory surgical setting.
 
Dr. David Murphy, DPM FACFAS told the press, “Hammerdesis provides patients with a more reliable, and a more consistent option to fix hammertoe issues. My surgeon colleagues and I are excited to use this novel system, and I am looking forward to seeing our patients benefit from Hammerdesis.”
 
Intelivation’s president Amit Sinha added, “There is nothing on the market today like the Hammerdesis procedure. This is a truly disruptive technology in a crowded area. Our product development and sales teams are looking forward to being a part of this market transformation that will make a major impact for surgeons and their patients for many years to come. We are currently preparing for our launch and post-market clinical data points to share with the orthopedic and podiatric communities.”
 
The company said it will be showcasing the product and others at next year’s American College of Foot and Ankle Surgeons (ACFAS) meeting in February.